2022
Personalized medicine and disorders of consciousness
Fins J. Personalized medicine and disorders of consciousness. 2022, 131-140. DOI: 10.1093/oso/9780198863465.003.0010.Peer-Reviewed Original ResearchPersonalized medicineNext-generation personalized medicineDisorders of consciousnessDevelopment of therapeuticsDomain of personalized medicineAccurate diagnostic classificationPathological phenotypesUnique biologyTherapeutic responseMolecular levelIndividual diseasesGuiding treatmentCare of patientsPersonalized therapySide effectsTherapeutic effectMinimally conscious stateBiological characteristicsMolecular biomarkersBiologyDiseaseCharacterize diseaseNeural circuitryPatientsDiagnostic classification
2018
Co-occurring Substance and Mental Health Disorders
Jorandby-Quinones L, Edens E, Rosenheck R. Co-occurring Substance and Mental Health Disorders. 2018, 307-333. DOI: 10.1007/978-1-4939-7438-2_20.ChaptersDual diagnosisMental health care deliveryHigh treatment burdenMore medical conditionsMental health care systemMental health disordersSubstance use disordersCo-occurring substanceEvolution of treatmentHealthcare delivery approachHealth care deliveryHealth care systemTreatment burdenMedical conditionsUse disordersHealth disordersMedical carePatientsCare deliveryPsychosocial conditionsIndividual diseasesCare systemDiagnosisTreatmentDisease
2017
From Reproducibility to Translation in Neurodegenerative Disease.
Zeiss CJ. From Reproducibility to Translation in Neurodegenerative Disease. ILAR Journal 2017, 58: 106-114. PMID: 28444192, DOI: 10.1093/ilar/ilx006.Peer-Reviewed Original ResearchConceptsNeurodegenerative diseasesPreclinical studiesDisease-altering treatmentsComplex human neurodegenerative diseasesBody of evidenceAnimal study designHuman neurodegenerative diseasesOutcome measuresTherapeutic studiesPreclinical successPharmacologic criteriaTherapeutic potentialStudy designDiseaseIndividual diseasesAnimal experimentsBiomarker dataTranslational purposesCell-based systemsConcept studyStudy design methodsPredictive validityPhenotypic variabilityPatientsStudy
2012
Contribution of Individual Diseases to Death in Older Adults with Multiple Diseases
Tinetti ME, McAvay GJ, Murphy TE, Gross CP, Lin H, Allore HG. Contribution of Individual Diseases to Death in Older Adults with Multiple Diseases. Journal Of The American Geriatrics Society 2012, 60: 1448-1456. PMID: 22734792, PMCID: PMC3419332, DOI: 10.1111/j.1532-5415.2012.04077.x.Peer-Reviewed Original ResearchConceptsOlder adultsSingle underlying causeRespiratory diseaseMedicare Current Beneficiary Survey participantsChronic lower respiratory diseasesUnderlying causeAcute kidney injuryLower respiratory diseaseAverage attributable fractionKidney injuryHazard ratioHeart failureLiver diseaseAcute eventMyocardial infarctionUnintentional injuriesAcute diseaseAttributable fractionNational representative sampleMedicare beneficiariesOlder adults' experiencesDiseaseIndividual diseasesDeathConfidence intervalsA method for partitioning the attributable fraction of multiple time-dependent coexisting risk factors for an adverse health outcome.
Lin H, Allore HG, McAvay G, Tinetti ME, Gill TM, Gross CP, Murphy TE. A method for partitioning the attributable fraction of multiple time-dependent coexisting risk factors for an adverse health outcome. American Journal Of Public Health 2012, 103: 177-82. PMID: 22515873, PMCID: PMC3518339, DOI: 10.2105/ajph.2011.300458.Peer-Reviewed Original ResearchConceptsHealth outcomesAttributable fraction methodPrecipitating Events ProjectAdverse health outcomesMultiple diseasesAcute episodeNew onsetHeart failureAdverse outcomesRisk factorsAttributable fractionNew Haven CountyDiseaseIndividual diseasesOlder adultsOutcomesAdditive effectDeathEvent outcomesOnsetPneumoniaCohort
2008
Current Status of Prognostic Profiling in Breast Cancer
Pusztai L. Current Status of Prognostic Profiling in Breast Cancer. The Oncologist 2008, 13: 350-360. PMID: 18448548, DOI: 10.1634/theoncologist.2007-0216.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsClinical Trials as TopicDNA Topoisomerases, Type IIDNA-Binding ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansOligonucleotide Array Sequence AnalysisOncogenesPredictive Value of TestsPrognosisReceptor, ErbB-2Receptors, EstrogenResearch DesignTamoxifenTaxoidsTreatment OutcomeConceptsBreast cancerClinical-pathological variablesClinical trial planningClinical courseClinical outcomesPathological variablesTreatment armsPrognostic informationClinical trialsTreatment strategiesClinicopathologic parametersHeterogeneous diseaseSpecific treatmentTherapeutic targetPrognostic profilingClinical heterogeneityGene expression fingerprintProspective tissue collectionAbnormal gene expressionIndividual tumorsPrognostic testTumorsPredictive indicatorIndividual diseasesTrial planning
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply